Related Experiment Videos
Anticoagulation in cardiac diseases. Prevention and control of thromboembolic events
Insights
Anticoagulant therapy is crucial for preventing blood clots in various heart conditions, including valvular heart disease and after prosthetic valve surgery. It is also recommended for acute cardiac events and heart failure management.
Area of Science:
- Cardiology
- Hematology
Background:
- Thrombosis is a frequent complication in patients with cardiac diseases.
- Anticoagulant therapy plays a vital role in managing and preventing thrombotic events in cardiovascular conditions.
Purpose of the Study:
- To outline the recommended use of anticoagulant therapy in various cardiac disease scenarios.
- To provide guidance on prophylaxis and treatment for thromboembolic events in cardiology.
Main Methods:
- Review of current guidelines and recommendations for anticoagulant therapy in valvular heart disease.
- Analysis of indications for anticoagulation in patients with prosthetic heart valves.
- Summary of anticoagulant use in acute myocardial infarction, unstable angina, and cardiac arrest.
- Evaluation of anticoagulation in chronic cardiomyopathy with heart failure or atrial fibrillation.
Main Results:
- Anticoagulant therapy is recommended for high-risk valvular heart disease patients to prevent initial or recurrent embolic episodes.
- Prophylaxis is advised for patients over 40 with valvular heart disease.
- Chronic oral anticoagulants are recommended post-surgery for prosthetic heart valves.
- Heparin is indicated for at least two weeks in acute transmural infarction, unstable angina, or sudden cardiac arrest.
- Anticoagulation is advised for chronic cardiomyopathy with congestive heart failure or atrial fibrillation.
Conclusions:
- Anticoagulant therapy is a cornerstone in the management of thrombosis across a spectrum of cardiac diseases.
- Tailored anticoagulant strategies are essential for preventing thromboembolic complications in high-risk cardiac patients.
Abstract:
Thrombosis is a common feature of cardiac diseases. In valvular heart disease, anticoagulant therapy is recommended to prevent an initial embolic episode in high-risk patients or recurrent episodes in patients who have had an embolic event. Prophylaxis is recommended for patients over age 40. For patients with prosthetic heart valves, chronic anticoagulant therapy is recommended immediately after surgery, followed by long-term use of oral anticoagulants. Moderate doses of subcutaneous or intravenous heparin should be given for at least two weeks in patients with acute transmural infarction, unstable angina, or sudden cardiac arrest. In addition, anticoagulation is currently recommended for use in patients with chronic cardiomyopathy associated with congestive heart failure or atrial fibrillation.